发现很多有绿卡的国女 也说 中国男人最差 (转载)# Piebridge - 鹊桥
c*o
1 楼
Email me at c*********[email protected]
With your name, brief background, email address.
Important: You need to register as a reviewer for European Journal of
Pharmaceutical Sciences
I will recommend first three who contact me before tonight.
Title: Hyaluronan as drug carrier. The in vitro efficacy and selectivity of
Hyaluronan-Doxorubicin complexes to affect the viability of overexpressing
CD44 receptor cells.
ABSTRACT:
We report Doxorubicin ionic complexes with hyaluronic acid (HiH-Dx) or its
sodium salt (HiNa-Dx) as tumor-targeting delivery system. The complexes were
prepared in situ by mixing aqueous solutions of Dx.HCl with HiH or HiNa.
Clear colloidal dispersions with a high degree of counterionic condensation
(cc) were obtained. Affinity constants (log Kcc) of HiNa-Dx and HiH-Dx were
7.96 and 8.08, respectively. Delivery rates of Dx from the complexes were
measured in a Franz-type bicompartimental device. In line with the high
affinity constants, loaded Dx was slowly released from the complexes.
To test the targeting potential of the complexes, carcinogenic A549 cells
overexpressing the CD44 receptors were used. HTR8/SVneo cells without
overexpression of CD44 were used as control. In A549 cells, cytotoxicity of
both HiH-Dx and HiNa-Dx complexes was 3-fold higher than that of the
reference solution. However, no differences were observed between the
complexes and free Dx solution in HTR8/SVneo cells. Flow cytometry data
suggested successful uptake of Dx in cells, with a greater internalization
of Dx in A549 cells than in HTR8/SVneo cells when the complexes were used.
Similarly, microscopy imagines revealed a higher concentration of Dx in A549
cells with the complexes.
This work provides more detailed information in order to contribute to more
solid bases to evaluate the potentiality of Hi as an antineoplastic drug
carrier convenient for being used in specific therapeutic indications with
minimal side effects.
With your name, brief background, email address.
Important: You need to register as a reviewer for European Journal of
Pharmaceutical Sciences
I will recommend first three who contact me before tonight.
Title: Hyaluronan as drug carrier. The in vitro efficacy and selectivity of
Hyaluronan-Doxorubicin complexes to affect the viability of overexpressing
CD44 receptor cells.
ABSTRACT:
We report Doxorubicin ionic complexes with hyaluronic acid (HiH-Dx) or its
sodium salt (HiNa-Dx) as tumor-targeting delivery system. The complexes were
prepared in situ by mixing aqueous solutions of Dx.HCl with HiH or HiNa.
Clear colloidal dispersions with a high degree of counterionic condensation
(cc) were obtained. Affinity constants (log Kcc) of HiNa-Dx and HiH-Dx were
7.96 and 8.08, respectively. Delivery rates of Dx from the complexes were
measured in a Franz-type bicompartimental device. In line with the high
affinity constants, loaded Dx was slowly released from the complexes.
To test the targeting potential of the complexes, carcinogenic A549 cells
overexpressing the CD44 receptors were used. HTR8/SVneo cells without
overexpression of CD44 were used as control. In A549 cells, cytotoxicity of
both HiH-Dx and HiNa-Dx complexes was 3-fold higher than that of the
reference solution. However, no differences were observed between the
complexes and free Dx solution in HTR8/SVneo cells. Flow cytometry data
suggested successful uptake of Dx in cells, with a greater internalization
of Dx in A549 cells than in HTR8/SVneo cells when the complexes were used.
Similarly, microscopy imagines revealed a higher concentration of Dx in A549
cells with the complexes.
This work provides more detailed information in order to contribute to more
solid bases to evaluate the potentiality of Hi as an antineoplastic drug
carrier convenient for being used in specific therapeutic indications with
minimal side effects.
